Zymo Research Europe’s Post

Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science

Missed out on this year's #ASMS conference? That doesn’t mean you have to miss out on the exciting science we shared! Check out this poster presented by Jeremiah Bowers, based on a collaboration with MOMA Therapeutics.      By leveraging cutting-edge proteomic technologies and mass spectrometry workflows developed by Momentum, Bowers and colleagues were able to identify and characterize several covalent cysteine modifiers active against cancer-driving helicases. Their research demonstrates the power of mass spec covalent binding screening, modification mapping, and occupancy calculations in taking a project from screening to hit characterization with unmatched efficiency.      Want to learn more about this project? Request the full poster here: https://lnkd.in/e6GFCEvW      #CancerResearch #DrugDiscovery #RapidFireMS, #OrbitrapAscend #Covalent #Chemoproteomics #Chemicalbiology

Nice paper by Denali Therapeutics, taking advantage of ATUM's orthogonal transposons Leap-In 1 and Leap-In 2. They compare co-transfection vs. supertransfection (transfection on a previously transfected pool) of Gene-of-Interest to increase titer in stable CHO. Show high expression efficiency with similar expression levels independent of transfection method. Supertransfection using orthogonal transposases is a valuable strategy for increasing titers or for overexpressing helper genes to improve the expression and/or product quality of existing pools, saving significant time and resources.

When discussing lipid nanoparticles (LNPs), we often focus on the drug payload, but the lipid components, their structure, and their impact on gene delivery are equally crucial. Cholesterol, the second most abundant component after ionizable lipids, plays a key role. Adding cholesterol improves delivery efficiency and enhances LNPs' ability to fuse with cell membranes and release their contents. To support researchers in their formulation and process scale-up studies, Corden Pharma - A Full-Service CDMO created #LNP starter kits. These kits provide up to 15 mL of a complete lipid mixture and offer a variety of lipid components, including cholesterol or its analogs. Evaluating #cholesterolanalogs is essential; for instance, researchers have studied LNPs containing naturally occurring phytosterols like β-sitosterol, stigmasterol, and stigmastanol. They discovered that incorporating these cholesterol analogs significantly changes the LNPs' structure and #improves #nucleicacid #delivery (Eygeris et al. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett. 2020 Jun 10;20(6):4543-4549.) Our starter kits make it easier to explore these variations and optimize LNP formulations for better performance. https://lnkd.in/eCubZwZA

Today marks the day of our webinar, "2023 Annual Meeting Poster Awardee Spotlight," featuring Anastasia Kremer and Linda Popella. Join us from 11-12 pm EST for a deep dive into their research. Kremer will speak on siRNA therapy for ex vivo treatment, and Popella will share insights on high-susceptibility targets of programmable RNA antibiotics. Don't miss this chance to stay informed about the latest developments in oligonucleotide therapeutics! https://lnkd.in/gHNPiiwc #OTS #oligotherapeutics #oligonucleotides #biotech #biotechnology #science #research #biology #pharma #sirna #rna #webinar #currentscience #healthinsights #stemcells

Don’t be left behind with your therapeutics research! With this free infographic, find out how a reverse translation approach produces a wealth of actionable insights to eliminate drug failure. Download it here: https://lnkd.in/eirEAXCQ #therapeutics #drugdevelopment #infographic Olink Proteomics

Developing oligonucleotide therapeutics? On the 21st May, I will be presenting a live webinar showcasing Patsnap's groundbreaking chemical modification search tool. Identifying modifications in sequences has previously been a laborious and incredibly time consuming task, but thanks to our comprehensive modification ontologies, and AI extraction model, these pains are a thing of the past. Come along to find out how we can revolutionise your oligonucleotide development. #RNA #oligonucleotide #innovation #chemicalmodification

If you are working on a biologic therapy for a #neurodegenerative disease or #stroke, consider registering for the upcoming #Blueprint #Neurotherapeutics for biologics (BPN-Biologics) Q&A webinar on Oct. 23 at 2pm ET. This would include biotechnology products and biologics-based therapies such as peptides, proteins, and antibodies, gene-based therapies such as oligonucleotide and viral based cell therapies, as well as other novel emerging therapies including microbial and microbiome therapies. #BPNBiologics provides #nondilutive funding and resources for drug discovery and development, from lead optimization through phase I clinical testing. Investigators interested in learning about the program can register here: https://lnkd.in/ezN-_r-U

Nucleic Acid Therapeutics (ahead of print, April 2024): Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′-O-Methyl Modified Single-Stranded #Oligonucleotides (SSOs) 💡 Study demonstrates a structure–cytotoxicity relationship and indicates that the formation of stable hairpins should be a consideration when designing SSOs toward optimal #therapeutic profiles https://lnkd.in/e3HGpJa4 #antisenseoligonucleotides #microRNA #aptamers #ASO #TIDES